Genetic Engineering & Biotechnology News

MAY15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 5 of 37

4 | MAY 15, 2017 | | Genetic Engineering & Biotechnology News 140 Huguenot Street, New Rochelle, NY 10801- 5215 914 740 -2100 • PUBLISHER & CEO Mary Ann Liebert PRESIDENT, GEN Publishing Marianne Russell EDITOR IN CHIEF John Sterling GEN GROUP PUBLISHER Sande Giaccone P R O D U C T I O N E D I TO R Robert M. Reis S E N I O R E D I TO R Kevin Mayer T E C H N I C A L E D I TO R Patricia F. Dimond, Ph.D. T E C H N I C A L E D I TO R Jeffrey S. Buguliskis, Ph.D. S E N I O R N E W S E D I TO R Alex Philippidis C H I E F CO PY E D I TO R Steven Hernacki A R T D I R E C TO R James Lambo COMMERCIAL DIREC TOR Bill Levine O N L I N E P R O D U C T M A N AG E R Thomas Mathew W E B P R O D U C E R Melinda Kucsera S A L E S A D M I N I S T R ATO R Fallon Murphy ONLINE COORDINATOR Katherine Vuksanaj GEN Editorial & Scientific Advisory Board Peter Banks, Ph.D., Scientific Director, BioTek Instruments; Roslyn Brandon, D.V.M., Ph.D., President and CEO, Immunexpress; Robert Clarke, Ph.D., President & CEO, Pulmatrix; Pete Gagnon, Project Director, Downstream Processing, Bioprocessing Technology Institute (Singapore); Uwe Gottschalk, Ph.D., CTO, Lonza Pharma & Biotech; Harry E. Gruber, M.D., CEO, Tocagen; Jin Seok Hur, Ph.D., Technology Director, Novasep; James Inglese, Ph.D., Principal Investigator, Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences NIH; Guenter Jagschies, Senior Director, GE Healthcare Life Sciences; Peter Johnson, M.D., Principal, MedSurgPI; Anis H. Khimani, Ph.D., Head of Strategy & Marketing, Research Reagent Solutions, PerkinElmer; Mikael Kubista, Ph.D., Biotechnology Institute, Academy of Sciences, Czech Republic; Peter Levison, Senior Marketing Director, Downstream Processing, Pall Life Sciences; Jan Lichtenberg, Ph.D., CEO and Co-Founder, InSphero; Miodrag Micic, Sc.D., Ph.D., Professor and Department Chairman, Cerritos College; Eric Schadt, Ph.D., Director, Icahn Institute for Genomics and Multiscale Biology; Zhiwei Song, Ph.D., Scientist, National University of Singapore; Sumio Sugano, M.D., Ph.D., Professor, Medical Genomics, University of Tokyo; John Talley, Ph.D., CSO, SARmont; Bin Wang, Ph.D., Professor, Principal Investigator, Fudan University Shanghai Medical College; Daniel I. C. Wang, Ph.D., Institute Professor of Chemical Engineering, MIT Advertising United States and North America EAST COAST Monica Lieberman 914 740 2173 SF BAY AREA Sharon Spitz 314 795 4151 MIDWEST/S.EAST Rick Bongiovanni 330 998 9800 WEST COAST Catherine McConville 415 416 8970 U.K. and Europe Ian Slade +44 7768 397068 GEN Classified, Asia and Australia Display Victoria Palusevic 914 740 2167 All Other Countries 914 740 2200 Insertions and Advertising Material Wanda Sanchez Customer Service & Subscriptions 888 211 4235 847 559 7587 Reprints Karen Ballen 914 740 2100 The views, opinions, findings, conclusions, and recommendations set forth in any article in Genetic Engineering & Biotechnology News (GEN) are solely those of the authors of those articles and do not necessarily reflect the views, policy, or position of GEN, its Publisher, or its editorial staff and should not be attributed to any of them. All advertisements are subject to review by the Publisher. The acceptance of advertisements does not constitute an endorsement of the product or service advertised. Genetic Engineering & Biotechnology News (ISSN-1935-472X) is published semimonthly except July, August, and December (twenty-one issues a year) by GEN Publishing, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801-5215. Periodicals postage paid at New Rochelle, NY and at additional mailing offices. Postmaster: Send address changes to Genetic Engineering & Biotechnology News, c/o Subscription Department, Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle, New York 10801-5215. Fax: 914 740-2201. Mailed in Canada under CPC CPM #40026674. Printed in the U.S.A. For subscription information go to: Copyright © 2017 by GEN Publishing, New Rochelle, NY. Mary Ann Liebert, Inc. is recognized as a Certified Woman-Owned Business by the Women's Business Enterprise National Council (WBENC). Results from a new study published in Nature Neuro- science suggests that humans spend a lot more time dreaming while asleep than previously thought. Rapid eye movement, or REM, sleep was thought to represent the primary dream stage. However, in this recent study investigators found that 71% of non-REM sleep time— the bulk of sleep—was spent dreaming. Using an electroencephalogram cap, researchers spotted a previously undetected signal in sleepers from the poster portion of the brain they dubbed the "hot zone." The scientists found a robust relationship between dreaming and fewer low-frequency waves within the "hot zone," which allowed them to successfully predict dream states greater than 90% of the time. The researchers are optimistic that their results could have a beneficial impact on a variety of sleep-related health issues. A king of shreds and patches is no king at all. And a giant cell-like virus of genomic scraps is no cell at all—not even a much-diminished version of a long-extinct life form. Which is to say, giant viruses do not appear to have devolved from a fourth domain of life, as some have proposed. Rather, they seem to have evolved by accretion, snatching genes from different hosts over time—and relatively recently, in evolutionary terms. That giant vi- ruses are hoarders, not ruined royals, is the conclusion of a recent paper in Science. Contributed by Joint Genome Institute scientists, the paper reports that newly found giant viruses, Klosneuviruses, encode translation system components that can be traced to various host genomes. These viruses were discovered—fittingly enough, given their grossly gluttonous nature—in sewage sludge. Kevin Davies, Ph.D., Joins Mary Ann Liebert, Inc. GEN is pleased to announce that Kevin Davies, Ph.D., has joined Mary Ann Liebert, Inc., publishers, as executive vice president, strategic development. Dr. Davies is an accomplished editor, author, and publisher who specializes in genomics and personalized medicine. In April 2017, he won a prestigious Guggenheim Fellowship for science writing. A native of London, Dr. Davies studied biochemistry at the University of Oxford and received a Ph.D. in molecular genetics from St. Mary's Hospital Medical School (University of London), where he worked on mapping the cystic fibrosis gene. After postdoctoral fellowships at MIT and Harvard Medical School, Dr. Davies joined the editorial staff of Nature. Within two years, he was named the founding editor of Nature Genetics, the leading genetics journal, which debuted in 1992. Dr. Davies has held several prominent editorial and publishing positions since then, including Editor-in-Chief of Cell Press and launch editor for Bio-IT World, a sister magazine to Macworld covering Big Data in the life sciences. Most recently, Dr. Davies was a vice president of the American Chemical Society, where he helped launch two new open-access journals and was publisher of the weekly magazine Chemical & Engineering News. Dr. Davies is the author (or co-author) of three popular science books exploring the medical and societal impact of advances in DNA sequencing and analysis, including Breakthrough: The Race to Find the Breast Cancer Gene (Wiley, 1995) and Cracking the Genome: The Race to Unlock Human DNA (Free Press, 2001)—the first published account of the Human Genome Project saga that was translated into 16 different languages. The $1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine (Free Press, 2010) explored the advances in DNA sequencing and consumer genetics. Dr. Davies is the co-author with Nobel laureate Jim Watson of an updated edition of DNA: The Story of the Genetics Revolution (Knopf, August 2017). "I am delighted to be joining the Mary Ann Liebert team," said Dr. Davies. "I have long admired the company's penchant for identifying emerging areas of science and medicine, and sought to emulate the long-standing success of Genetic Engineering and Biotechnology News. I hope my ideas and experience in launching new journals and managing various science and technology publications will help the Liebert organization grow and flourish in the years ahead." Sticky Ends ... Comstock Images/Getty Images Giant Viruses Flaunt Ragtag Genomes Fungi are a potential gold mine for the production of pharmaceuticals. Chalm- ers University of Technology scientists, writing in Nature Microbiology, have developed a method for finding new antibiotics from nature's own resources. The researchers scanned the ge- nomes of 24 different kinds of fungi to find genes responsible for the produc- tion of various bioactive compounds, like antibiotics. More than 1,000 path- ways were discovered, showing im- mense potential for fungi to produce a large variety of natural and bioactive chemicals that could be used as phar- maceuticals. In about 90 cases, the investigators were able to predict the chemical products of the pathways. As evidence of this, they followed the production of the antibiotic, yanut- hone, and identified new fungi able to produce the compound, but also that some species could produce a new version of the drug. Fungi Offer Opportunities for New Antibiotics 4 | MAY 15, 2017 | | Genetic Engineering & Biotechnology News Sleeping Full of Dreaming Sleeping Full of Dreaming

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - MAY15 2017